MXPA02005196A - Inhibidores de deacetilasa de histona. - Google Patents

Inhibidores de deacetilasa de histona.

Info

Publication number
MXPA02005196A
MXPA02005196A MXPA02005196A MXPA02005196A MXPA02005196A MX PA02005196 A MXPA02005196 A MX PA02005196A MX PA02005196 A MXPA02005196 A MX PA02005196A MX PA02005196 A MXPA02005196 A MX PA02005196A MX PA02005196 A MXPA02005196 A MX PA02005196A
Authority
MX
Mexico
Prior art keywords
histone deacetylase
inhibitors
methods
inhibition
conditions
Prior art date
Application number
MXPA02005196A
Other languages
English (en)
Inventor
Delorme Daniel
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MXPA02005196A publication Critical patent/MXPA02005196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
MXPA02005196A 1999-11-23 2000-11-22 Inhibidores de deacetilasa de histona. MXPA02005196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16703599P 1999-11-23 1999-11-23
PCT/IB2000/001881 WO2001038322A1 (en) 1999-11-23 2000-11-22 Inhibitors of histone deacetylase

Publications (1)

Publication Number Publication Date
MXPA02005196A true MXPA02005196A (es) 2003-09-22

Family

ID=22605679

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005196A MXPA02005196A (es) 1999-11-23 2000-11-22 Inhibidores de deacetilasa de histona.

Country Status (11)

Country Link
US (3) US6541661B1 (es)
EP (2) EP1233958B1 (es)
JP (2) JP2003514904A (es)
KR (4) KR20070053362A (es)
AT (1) ATE514674T1 (es)
AU (1) AU783504C (es)
CA (1) CA2391952C (es)
DK (1) DK1233958T3 (es)
MX (1) MXPA02005196A (es)
PT (1) PT1233958E (es)
WO (1) WO2001038322A1 (es)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
AU2001248701A1 (en) * 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
AU2001290134A1 (en) * 2000-09-29 2002-04-08 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
BR0212510A (pt) * 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US20040072735A1 (en) 2002-03-04 2004-04-15 Richon Victoria M. Methods of inducing terminal differentiation
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
ATE458047T1 (de) 2002-03-07 2010-03-15 Univ Delaware Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
DK1485354T3 (da) * 2002-03-13 2008-09-01 Janssen Pharmaceutica Nv Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
JP4674045B2 (ja) * 2002-03-13 2011-04-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのピペラジニル−、ピペリジニル−およびモルホリニル−誘導体
BR0307624A (pt) * 2002-03-13 2005-01-11 Janssen Pharmaceutica Nv Inibidores de histona desacetilase
OA12789A (en) * 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Carbonylamino-derivatives as novel inhibitors of histone deacetylase.
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
NZ536116A (en) * 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2003273701A1 (en) 2002-10-17 2004-05-04 Methylgene Inc. Inhibitors of histone deacetylase
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
TW200418825A (en) * 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
AU2004205372B2 (en) 2003-01-17 2011-02-24 Topotarget Uk Limited Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
AU2003900587A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
KR100945959B1 (ko) 2003-04-07 2010-03-05 파마시클릭스, 인코포레이티드 치료제로서 히드록사메이트
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005007111A2 (en) * 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7368572B2 (en) 2003-08-20 2008-05-06 Pharmacyclics, Inc. Acetylene derivatives as inhibitors of histone deacetylase
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
WO2005023179A2 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
SI1673349T1 (sl) * 2003-09-22 2010-10-29 S Bio Pte Ltd Derivati benzimidazola: priprava in farmacevtske uporabe
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
AU2004276337B2 (en) * 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP1677731A4 (en) * 2003-10-09 2009-05-06 Aton Pharma Inc THIOPHENE AND BENZOTHIOPHENE DERIVATIVES OF HYDROXAMIC ACID
WO2005055928A2 (en) 2003-12-02 2005-06-23 The Ohio State University Research Foundation Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
EP1541549A1 (en) * 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US20080057529A1 (en) * 2003-12-18 2008-03-06 Michele Pallaoro Method for Identifying Histone Deacetylase Inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
GB0402496D0 (en) * 2004-02-04 2004-03-10 Argenta Discovery Ltd Novel compounds
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
CN1926103B (zh) * 2004-03-11 2012-12-19 4Sc股份公司 磺酰基吡咯作为hdac抑制剂
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
JP5319113B2 (ja) 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
EP1758880A1 (en) 2004-06-14 2007-03-07 F.Hoffmann-La Roche Ag Hydroxamates, their manufacture and use as pharmaceutical agents
EP1778683A1 (en) 2004-06-14 2007-05-02 F.Hoffmann-La Roche Ag Thiophene derivatives, their manufacture and use as pharmaceutical agents
US7423060B2 (en) 2004-06-14 2008-09-09 Hoffman-La Roche Inc. Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors
JP2008505969A (ja) * 2004-07-12 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素の阻害剤
CN101018547A (zh) * 2004-07-19 2007-08-15 默克公司 组蛋白脱乙酰基酶抑制剂
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2576667A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
ITMI20041869A1 (it) 2004-10-01 2005-01-01 Dac Srl Nuovi inibitori delle istone deacetilasi
ITMI20060621A1 (it) * 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
US8242175B2 (en) 2004-10-01 2012-08-14 Dac S.R.L. Class of histone deacetylase inhibitors
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
AU2006214319A1 (en) 2005-02-14 2006-08-24 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
EP1855111A4 (en) * 2005-03-02 2008-10-01 Astellas Pharma Inc NEW PD MARKER FOR HISTONE DEACETYLASE INHIBITOR
DK1861365T3 (da) 2005-03-15 2009-08-24 4Sc Ag N-sulfonylpyrroler og anvendelse deraf som histondeacetylaseinhibitorer
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
AU2006232773B2 (en) * 2005-04-07 2012-04-12 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
AU2006240248A1 (en) * 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
CA2605110A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
WO2006115833A1 (en) * 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
DK2494969T3 (en) 2005-05-13 2015-06-15 Topotarget Uk Ltd Pharmaceutical formulations of the HDAC inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
CA2612420A1 (en) 2005-06-24 2007-01-04 Merck & Co., Inc. Modified malonate derivatives
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1928826B1 (en) 2005-09-21 2013-04-24 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007039404A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US8828392B2 (en) * 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007213018A1 (en) 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
CN101528679A (zh) 2006-02-14 2009-09-09 哈佛大学校长及研究员协会 组蛋白去乙酰化酶抑制剂
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007234843B2 (en) 2006-04-07 2013-07-11 Methylgene Inc. Inhibitors of histone deacetylase
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
JP2009535333A (ja) 2006-04-26 2009-10-01 メルク エンド カムパニー インコーポレーテッド 二置換アニリン化合物
JP5497431B2 (ja) * 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009537529A (ja) 2006-05-18 2009-10-29 メルク エンド カムパニー インコーポレーテッド アリール縮合スピロ環化合物
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
TW200808707A (en) * 2006-06-14 2008-02-16 Methylgene Inc Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
AU2007275743A1 (en) 2006-07-20 2008-01-24 Merck Sharp & Dohme Corp. Phosphorus derivatives as histone deacetylase inhibitors
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008036046A1 (en) 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
SI2343286T1 (sl) 2006-10-28 2015-05-29 Methylgene Inc. Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
ES2509342T3 (es) 2006-10-30 2014-10-17 Chroma Therapeutics Limited Hidroxamatos como inhibidores de histona desacetilasa
EP2099756A1 (en) * 2006-12-15 2009-09-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008074132A1 (en) * 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
CA2677000A1 (en) 2007-01-30 2008-08-07 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
EP2124916A1 (en) * 2007-02-27 2009-12-02 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
TWI539947B (zh) * 2007-04-09 2016-07-01 米希爾金尼公司 組蛋白去乙醯基酶之抑制劑
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8008344B2 (en) 2007-09-14 2011-08-30 NatureWise Biotech and Medicals Corporation Compounds for the inhibition of histone deacetylase
US8440830B2 (en) 2007-09-19 2013-05-14 4Sc Ag Tetrahydro-fused pyridines as histone deacetylase inhibitors
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
BRPI0817860A2 (pt) 2007-10-22 2019-09-24 Orchid Res Laboratories Limited inibidores de histona deacetilase
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
WO2009055917A1 (en) * 2007-11-02 2009-05-07 Methylgene Inc. Inhibitors of histone deacetylase
US20110044952A1 (en) * 2007-11-27 2011-02-24 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
WO2009079375A1 (en) 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
WO2009095324A1 (en) 2008-01-29 2009-08-06 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-amide derivatives
JP5615189B2 (ja) * 2008-03-07 2014-10-29 トポターゲット アー／エス ベリノスタットの長期持続注入を用いた治療方法
EP2100882A1 (en) 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
BRPI0912399A2 (pt) 2008-05-16 2016-01-12 Hoffmann La Roche n-(2-amino-fenil)-acrilamidas
AU2009274549B2 (en) * 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
JP5769627B2 (ja) * 2008-10-15 2015-08-26 ジェネリクス・［ユーケー］・リミテッド ボリノスタットの調製方法
CN102282126A (zh) 2008-11-26 2011-12-14 基因里克斯(英国)有限公司 多晶型物
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
KR20110117194A (ko) 2009-02-23 2011-10-26 에프. 호프만-라 로슈 아게 암 치료를 위한 신규한 오르토-아미노아미드
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
WO2010108058A2 (en) 2009-03-20 2010-09-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Small molecule inhibitors of dusp6 and uses therefor
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2236503B1 (en) 2009-04-03 2014-02-26 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CA2765678A1 (en) * 2009-06-22 2010-12-29 Christopher Blackburn Substituted hydroxamic acids and uses thereof
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011021209A1 (en) * 2009-07-07 2011-02-24 Portsmouth Technologies Llc Histone deacetylase inhibitors
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
NZ599757A (en) 2009-10-30 2014-08-29 Massachusetts Inst Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
KR200454001Y1 (ko) * 2009-11-03 2011-06-10 주식회사 한길테크 수위조절장치
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106627A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012027564A1 (en) 2010-08-26 2012-03-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
US10160705B2 (en) * 2011-02-10 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2012112447A2 (en) * 2011-02-14 2012-08-23 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2828524C (en) * 2011-02-28 2020-01-07 Repligen Corporation Histone deacetylase inhibitors
JP5707518B2 (ja) 2011-02-28 2015-04-30 カリトル サイエンシズ， エルエルシー 置換型キノリン化合物及び使用方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
CA2876246C (en) 2012-07-28 2019-05-07 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
WO2014071000A1 (en) 2012-10-31 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
AU2014219256B2 (en) 2013-02-21 2017-02-16 Sunshine Lake Pharma Co., Ltd. Heteroaromatic compounds as PI3 kinase modulators
AU2014228344C1 (en) 2013-03-15 2019-02-07 Biomarin Pharmaceutical Inc. HDAC inhibitors
WO2014138989A1 (en) * 2013-03-15 2014-09-18 Methylgene Inc. Method and intermediates for the synthesis of hydroxamic acid compounds
WO2015017812A1 (en) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Methods for the treatment of solid tumors
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
CR20170420A (es) 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
CN105237444B (zh) * 2015-09-24 2018-03-30 沈阳药科大学 异羟肟酸类化合物及其制备方法和用途
AU2016343517B2 (en) 2015-10-19 2020-04-30 Sunshine Lake Pharma Co., Ltd. A salt of EGFR inhibitor, crystalline form and uses thereof
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
CN109641859A (zh) * 2016-06-21 2019-04-16 墨尔本大学 Hiv潜伏的激活剂
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
CN111072582A (zh) * 2018-10-18 2020-04-28 中国药科大学 一种n－羟基芳杂环－2－甲酰胺化合物及其制备方法和用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202011537D0 (en) * 2020-07-24 2020-09-09 Univ Newcastle Compounds
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
CN115304513A (zh) * 2022-08-25 2022-11-08 湖北科技学院 具有抗炎活性的查尔酮类衍生物及其合成方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB239863A (en) 1924-09-10 1925-11-19 Rachlis Dupin & Cie Sa Improvements in speed-changing system for cycle vehicles
US2279560A (en) 1940-05-08 1942-04-14 Du Pont Viscous hydrocarbon oil
US2279973A (en) 1940-05-08 1942-04-14 Du Pont Stabilization of organic substances
DE855866C (de) * 1950-12-16 1952-11-17 Schering Ag Verfahren zur Herstellung von o-Oxybenzhydroxamsaeuren
US2754286A (en) 1951-10-15 1956-07-10 Du Pont Aldehydes and their acetals
US4173577A (en) * 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
US4035376A (en) 1972-10-24 1977-07-12 Janssen Pharmaceutica N.V. Aroyl-substituted phenylacetic acid derivatives
BE826017R (fr) * 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
JPS5436229A (en) * 1977-08-25 1979-03-16 Hokuriku Pharmaceutical Substituted acetohydroxam derivative
JPS5651144A (en) 1979-10-03 1981-05-08 Nippon Telegr & Teleph Corp <Ntt> Station address control system
JPS5651441A (en) * 1979-10-05 1981-05-09 Nissan Chem Ind Ltd O- n-allyl-2,6-dichloroanilino phenylacetic acid derivative and its preparation
GB8531839D0 (en) 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
US4792560A (en) 1985-04-03 1988-12-20 Rorer Pharmaceutical Corporation Quinoline hydroxamates and their use as modulators of arachidonic acid metabolic pathways
US4994479A (en) 1985-04-03 1991-02-19 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives and anti-allergic use thereof
GB8820185D0 (en) 1988-08-25 1988-09-28 Wellcome Found New medical use
US5364944A (en) 1989-10-27 1994-11-15 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid compounds
US5218124A (en) 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5028629A (en) 1990-03-28 1991-07-02 Eli Lilly And Company 5-Lipoxygenase inhibitors
JPH04217950A (ja) * 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
FR2677984B1 (fr) 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
JP3342485B2 (ja) 1991-12-10 2002-11-11 塩野義製薬株式会社 芳香族スルホンアミド系ヒドロキサム酸誘導体
AT397908B (de) 1991-12-23 1994-08-25 Zengerer Johannes Staubsauger
TW281669B (es) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
US5538777A (en) 1993-09-01 1996-07-23 Marley Mouldings Inc. Triple extruded frame profiles
WO1995013264A1 (fr) 1993-11-08 1995-05-18 Terumo Kabushiki Kaisha Derive d'acide hydroxamique et preparation medicamenteuse contenant ledit derive
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
AU712801B2 (en) 1995-09-20 1999-11-18 Merck Sharp & Dohme Corp. Histone deacetylase as target for antiprotozoal agents
US5702811A (en) * 1995-10-20 1997-12-30 Ho; Kwok-Lun High performance abrasive articles containing abrasive grains and nonabrasive composite grains
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
DK0938471T3 (da) 1996-10-16 2002-01-28 American Cyanamid Co Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU5692398A (en) * 1996-12-09 1998-07-03 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
JPH10182583A (ja) * 1996-12-25 1998-07-07 Mitsui Chem Inc 新規ヒドロキサム酸誘導体
CA2279331C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002515900A (ja) 1997-03-04 2002-05-28 モンサント カンパニー 芳香族スルホニルアルファ−ヒドロキシヒドロキサム酸化合物
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
RU2200154C2 (ru) 1997-12-12 2003-03-10 Дайичи Файн Кемикал Ко., Лтд. Новые ингибиторы металлопротеиназ
EP1054877A1 (en) * 1998-02-11 2000-11-29 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
AU3312100A (en) * 1999-03-22 2000-10-09 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
KR20020009610A (ko) 1999-05-12 2002-02-01 윌리암스 로저 에이 매트릭스 메탈로프로테아제 억제제로서의 히드록삼산 유도체
YU22402A (sh) * 1999-09-08 2006-01-16 Sloan-Kettering Institute For Cancer Research Nova klasa agenasa za citodiferencijaciju i inhibitora histon deacetilaze, i postupci za njihovu upotrebu
AU3263201A (en) 1999-11-24 2001-06-04 University Of Hawaii Beam-steerer using reconfigurable pbg ground plane
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001290131B2 (en) * 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US20040072770A1 (en) 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8

Also Published As

Publication number Publication date
DK1233958T3 (da) 2011-10-17
KR20070053362A (ko) 2007-05-23
AU783504C (en) 2006-08-03
JP2010013443A (ja) 2010-01-21
PT1233958E (pt) 2011-09-20
WO2001038322A1 (en) 2001-05-31
EP1748046A3 (en) 2007-08-22
CA2391952A1 (en) 2001-05-31
AU1876801A (en) 2001-06-04
KR20020070285A (ko) 2002-09-05
CA2391952C (en) 2012-01-31
KR101026205B1 (ko) 2011-03-31
KR20090007495A (ko) 2009-01-16
US6541661B1 (en) 2003-04-01
USRE39850E1 (en) 2007-09-18
JP5290065B2 (ja) 2013-09-18
KR20100035666A (ko) 2010-04-05
EP1233958A1 (en) 2002-08-28
AU783504B2 (en) 2005-11-03
JP2003514904A (ja) 2003-04-22
USRE43343E1 (en) 2012-05-01
ATE514674T1 (de) 2011-07-15
EP1233958B1 (en) 2011-06-29
EP1748046A2 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
PT1233958E (pt) Inibidores de histona desacetilase
MXPA04002397A (es) Inhibidores de histona deacetilasa.
AU2001248701A1 (en) Inhibitors of histone deacetylase
DE602004026407D1 (en) Histondeacetylase-hemmer
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
BG104780A (en) Inhibitors of phospholipase enzymes
MXPA06010900A (es) Inhibidores de histona desacetilasa.
BG106020A (en) Inhibitors of impdh enzyme
IL137219A0 (en) Potassium channel inhibitors
MY138140A (en) N-aroylphenylalanine derivatives
EP1163208A4 (en) CASPASE INHIBITORS AND THEIR USE
SG55137A1 (en) Saccharin derivative proteolytic enzyme inhibitors
IL128205A0 (en) Potassium channel inhibitors and pharmaceutical compositions containing the same
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
NO996578L (no) Urokinase-inhibitorer
SG52659A1 (en) Saccharin derivative proteolytic enzyme inhibitors
MXPA05011286A (es) Derivados de acetileno como inhibidores de histona deacetilasa.
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
TW200602047A (en) Inhibitors of histone deacetylase
SE0302965D0 (sv) Hämmare av DNA-Metyltransferasisoformer
EP1047676A4 (en) SUBSTITUTED 11-PHENYL-DIBENZACEPINE COMPOUNDS, USEFUL FOR TREATING OR PREVENTING DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status